All of SphingoTec's biomarkers are globally patent protected
SphingoTec’s biomarkers are broadly validated and published in peer-reviewed journals
SphingoTec’s management builds on an extraordinary track-record in R&D and commercialization of novel diagnostic solutions
Innovative acute care biomarkers
Following a deep understanding of disease biology, SphingoTec develops novel biomarkers addressing diagnostically underserved critical care conditions such sepsis, acute heart failure, acute kidney injury, and cardiogenic shock.
Point-of-care testing with Nexus IB10 Analyzer
The CE-IVD marked Nexus IB10 platform is a fully automated rapid immunoassay point-of-care instrument. With a hands-on-time of less than 3 minutes the easy-to-use system provides in only 20 minutes test results for biomarkers that are crucial in the management of critical care patients.
Biomarkers and the management of COVID-19 patients
The global COVID-19 pandemic has challenged health systems world-wide, with about 5% of patients requiring admission to intensive care units (ICU). Read more on the importance of novel and established biomarker assays in the management of critically ill COVID-19 patients.
10:59 - 11:00
09:00 - 09:00
09:00 - 13:18